1s63
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 1s63 |SIZE=350|CAPTION= <scene name='initialview01'>1s63</scene>, resolution 1.90Å | |PDB= 1s63 |SIZE=350|CAPTION= <scene name='initialview01'>1s63</scene>, resolution 1.90Å | ||
|SITE= | |SITE= | ||
| - | |LIGAND= <scene name='pdbligand= | + | |LIGAND= <scene name='pdbligand=778:4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE'>778</scene>, <scene name='pdbligand=FPP:FARNESYL+DIPHOSPHATE'>FPP</scene>, <scene name='pdbligand=SUC:SUCROSE'>SUC</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> |
| - | |ACTIVITY= [http://en.wikipedia.org/wiki/Protein_farnesyltransferase Protein farnesyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.5.1.58 2.5.1.58] | + | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Protein_farnesyltransferase Protein farnesyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.5.1.58 2.5.1.58] </span> |
|GENE= FNTA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]), FNTB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | |GENE= FNTA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]), FNTB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY=[[1d8d|1D8D]], [[1ft1|1FT1]], [[1ld7|1LD7]], [[1ld8|1LD8]], [[1n4q|1N4Q]], [[1o5m|1O5M]], [[1s64|1S64]] | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1s63 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1s63 OCA], [http://www.ebi.ac.uk/pdbsum/1s63 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1s63 RCSB]</span> | ||
}} | }} | ||
| Line 26: | Line 29: | ||
[[Category: Casey, P J.]] | [[Category: Casey, P J.]] | ||
[[Category: Long, S B.]] | [[Category: Long, S B.]] | ||
| - | [[Category: 778]] | ||
| - | [[Category: FPP]] | ||
| - | [[Category: SUC]] | ||
| - | [[Category: ZN]] | ||
[[Category: caax]] | [[Category: caax]] | ||
[[Category: cancer]] | [[Category: cancer]] | ||
| Line 41: | Line 40: | ||
[[Category: ra]] | [[Category: ra]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 23:37:54 2008'' |
Revision as of 20:37, 30 March 2008
| |||||||
| , resolution 1.90Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | , , , | ||||||
| Gene: | FNTA (Homo sapiens), FNTB (Homo sapiens) | ||||||
| Activity: | Protein farnesyltransferase, with EC number 2.5.1.58 | ||||||
| Related: | 1D8D, 1FT1, 1LD7, 1LD8, 1N4Q, 1O5M, 1S64
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Human protein farnesyltransferase complexed with L-778,123 and FPP
Overview
Many signal transduction proteins that control growth, differentiation, and transformation, including Ras GTPase family members, require the covalent attachment of a lipid group by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type-I (GGTase-I) for proper function and for the transforming activity of oncogenic mutants. FTase inhibitors are a new class of potential cancer therapeutics under evaluation in human clinical trials. Here, we present crystal structures of the clinical candidate L-778,123 complexed with mammalian FTase and complexed with the related GGTase-I enzyme. Although FTase and GGTase-I have very similar active sites, L-778,123 adopts different binding modes in the two enzymes; in FTase, L-778,123 is competitive with the protein substrate, whereas in GGTase-I, L-778,123 is competitive with the lipid substrate and inhibitor binding is synergized by tetrahedral anions. A comparison of these complexes reveals that small differences in protein structure can dramatically affect inhibitor binding and selectivity. These structures should facilitate the design of more specific inhibitors toward FTase or GGTase-I. Finally, the binding of a drug and anion together could be applicable for developing new classes of inhibitors.
About this Structure
1S63 is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes., Reid TS, Long SB, Beese LS, Biochemistry. 2004 Jul 20;43(28):9000-8. PMID:15248757
Page seeded by OCA on Sun Mar 30 23:37:54 2008
